O
Olivier Boyer
Researcher at French Institute of Health and Medical Research
Publications - 171
Citations - 6245
Olivier Boyer is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Immune system & T cell. The author has an hindex of 39, co-authored 154 publications receiving 4850 citations. Previous affiliations of Olivier Boyer include Pierre-and-Marie-Curie University & University of Rouen.
Papers
More filters
Journal ArticleDOI
Single domain antibodies: promising experimental and therapeutic tools in infection and immunity.
Janusz Wesolowski,Vanina Alzogaray,Jan Reyelt,Mandy Unger,Karla Juarez,Karla Juarez,Mariela Urrutia,Ana Cauerhff,Welbeck Danquah,Björn Rissiek,Felix Scheuplein,Nicole Schwarz,Sahil Adriouch,Olivier Boyer,Michel Seman,Alexei Licea,David V. Serreze,Fernando Alberto Goldbaum,Friedrich Haag,Friedrich Koch-Nolte +19 more
TL;DR: The results of several recent proof-of-principle studies are reviewed that open the exciting perspective of using sdAbs for modulating immune functions and for targeting toxins and microbes.
Journal ArticleDOI
A Phase I/II Study of Herpes Simplex Virus Type 1 Thymidine Kinase "Suicide" Gene Therapy for Recurrent Glioblastoma
David Klatzmann,Charles A. Valéry,Gilbert Bensimon,Beatrice Marro,Olivier Boyer,Karima Mokhtari,Bertrand Diquet,Jean-Loup Salzmann,Jacques Philippon +8 more
TL;DR: Gene therapy based on retrovirus-mediated gene transfer of herpes simplex virus type 1 thymidine kinase (HSV-1 TK), which specifically sensitizes dividing cells to ganciclovir (GCV) toxicity, may help eradicate such cells.
Journal ArticleDOI
Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin.
Yves Allenbach,Laurent Drouot,Aude Rigolet,Jean Luc Charuel,Fabienne Jouen,Norma B. Romero,Thierry Maisonobe,Odile Dubourg,Anthony Behin,Pascal Laforêt,T. Stojkovic,Bruno Eymard,Nathalie Costedoat-Chalumeau,Emmanuelle Campana-Salort,Anne Tournadre,Lucile Musset,Brigitte Bader-Meunier,Isabelle Koné-Paut,Jean Sibilia,Laurent Servais,Olivier Fain,Claire Larroche,Elisabeth Diot,Benjamin Terrier,Raphael De Paz,Antoine Dossier,Dominique Menard,Chafika Morati,Marielle Roux,Xavier Ferrer,Jérémie Martinet,Sophie Besnard,Rémi Bellance,Patrice Cacoub,Laurent Arnaud,Bernard Grosbois,Serge Herson,Olivier Boyer,Olivier Benveniste +38 more
TL;DR: This study confirms the observation and description of anti-HMGCR aAb associated with NAM, and titers correlated with CK levels and muscle strength, suggesting their pathogenic role.
Journal ArticleDOI
High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody.
Yves Allenbach,Jeremy Keraen,Anne-Marie Bouvier,Valérie Jooste,Nicolas Champtiaux,Baptiste Hervier,Yoland Schoindre,Aude Rigolet,Laurent Gilardin,Lucile Musset,J.L. Charuel,Olivier Boyer,Fabienne Jouen,Laurent Drouot,Jérémie Martinet,Tanya Stojkovic,Bruno Eymard,Pascal Laforêt,Antony Behin,Emmanuelle Salort-Campana,Olivier Fain,Alain Meyer,Nicolas Schleinitz,Kuberaka Mariampillai,Aurélie Grados,Olivier Benveniste +25 more
TL;DR: Cancer screening is necessary in seronegative necrotizing autoimmune myopathies patients and in HMGCR-positive patients but not in anti-signal recognition particle- positive patients, because of the high incidence of cancer in these patients.
Journal ArticleDOI
The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation.
Alexa S. Green,Alexa S. Green,Nicolas Chapuis,Nicolas Chapuis,Thiago Trovati Maciel,Lise Willems,Lise Willems,Mireille Lambert,Mireille Lambert,Christophe Arnoult,Olivier Boyer,Valérie Bardet,Valérie Bardet,Sophie Park,Marc Foretz,Marc Foretz,Benoit Viollet,Benoit Viollet,Norbert Ifrah,François Dreyfus,Olivier Hermine,Ivan C. Moura,Catherine Lacombe,Catherine Lacombe,Patrick Mayeux,Patrick Mayeux,Didier Bouscary,Jerome Tamburini +27 more
TL;DR: The induction of the LKB1/AMPK/TSC tumor suppressor axis is functional in AML and can be activated by the biguanide molecule metformin, resulting in a specific inhibition of mammalian target of rapamycin catalytic activity.